LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells

International Journal of Gynecological Cancer

Volumn 22, Issue 1, 2012, Pages 15-22

  Li, Cuilan ^a   Liu, Vincent Wing Sun ^a   Chan, David Wai ^a   Yao, Kwok Ming ^a   Ngan, Hextan Yuen Sheung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

AKT; AMPK; LY294002; Metformin; MTOR; Ovarian cancer

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ACETYL COENZYME A CARBOXYLASE; CASPASE 3; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN; COLONY FORMATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; WESTERN BLOTTING;

ACETYL-COA CARBOXYLASE; AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; HUMANS; METFORMIN; MORPHOLINES; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; POLY(ADP-RIBOSE) POLYMERASES; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863229883     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182322834     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. (Pubitemid 40372904)
2. Konstantinopoulos PA, Spentzos D, Cannistra SA. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol. 2008;5:577-587.
3. Kelland LR. Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2005;10:413-424. (Pubitemid 40695136)
4. Blagden S, Gabra H. Promising molecular targets in ovarian cancer. Curr Opin Oncol. 2009;21:412-419.
5. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 2005;8:179-183. (Pubitemid 41317589)
6. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J. 2008;415:333-344.
7. Altomare DA, Wang HQ, Skele KL, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004;23:5853-5857. (Pubitemid 39093031)
8. Fraser M, Bai T, Tsang BK. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer. 2008;122:534-546. (Pubitemid 350308944)
9. Xing H, Weng D, Chen G, et al. Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett. 2008;261:108-119. (Pubitemid 351192224)
10. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007;8:774-785. (Pubitemid 47462132)
11. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009;89:1025-1078.
12. Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta. 2010;1804:581-591.
13. Gotlieb WH, Saumet J, Beauchamp MC, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 2008;110:246-250.
14. Rattan R, Giri S, Hartmann LC, et al. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 2011;15:166-178.
15. Yasmeen A, Beauchamp MC, Piura E, et al. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol. 2011;121:492-498.
16. Brenman JE. AMPK/LKB1 signaling in epithelial cell polarity and cell division. Cell Cycle. 2007;6:2755-2759. (Pubitemid 350277166)
17. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nature Reviews Cancer. 2009;9:563-575.
18. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909-918. (Pubitemid 41103603)
19. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22:2336-2347. (Pubitemid 41115390)
20. O'Donnell A, Faivre S, Burris HA 3rd, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008;26:1588-1595.
21. Ikezoe T, Nishioka C, Bandobashi K, et al. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res. 2007;31:673-682. (Pubitemid 46560001)
22. Schlosshauer PW, Li W, Lin KT, et al. Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells. Gynecol Oncol. 2009;114:516-522.
23. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304-1305. (Pubitemid 40813563)
24. Zakikhani M, Blouin MJ, Piura E, et al. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat. 2010;123:271-279.
25. Hahn-Windgassen A, Nogueira V, Chen CC, et al. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem. 2005;280:32081-32089. (Pubitemid 41361813)
26. Janjetovic K, Vucicevic L, Misirkic M, et al. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol. 2011;651:41-50.
27. Park HU, Suy S, Danner M, et al. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther. 2009;8:733-741.
28. Chhipa RR, Wu Y, Mohler JL, et al. Survival advantage of AMPK activation to androgen-independent prostate cancer cells during energy stress. Cell Signal. 2010;22:1554-1561.